×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Idea: Novel Therapy Index
idea
10,647 words
Contents
Novel Therapy Index
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (58)
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
Ganglioside Rebalancing Therapy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
R-Loop Resolution Enhancement Therapy
Score: 0.68
Arginine Methylation Enhancement Therapy
Score: 0.65
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.65
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.62
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
LRP1-Dependent Tau Uptake Disruption
Score: 0.60
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
Temporal Decoupling via Circadian Clock Reset
Score: 0.54
← Prev
pg 3/3
Related Analyses (22)
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 17 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Gandouling protection against brain injury in Wilson's disea
validation · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
Acteoside treatment in LPS-induced SALI mouse model
validation · proposed · Score: 0.90
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Multi-omics analysis of myricanol effects on gene expression
exploratory · proposed · Score: 0.88
AMPK knockdown validation experiment
exploratory · proposed · Score: 0.88
Acteoside effects on RAW264.7 macrophage cells
exploratory · proposed · Score: 0.85
Nrf2 inhibitor ML385 mechanism validation experiment
exploratory · proposed · Score: 0.85
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
iPSC-NPC transplantation in ICH animal model
validation · proposed · Score: 0.85
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Normal Aging to Alzheimer's Disease Transition Trigger — Ide
validation · proposed · Score: 0.40
s:** - Biochemical binding assays measuring PROTAC selectivi
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Epigenetic Clocks in Neurodegeneration — Causal Drivers or P
validation · completed · Score: 0.40
Show 25 more
See Also (15)
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 3 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 3 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 3 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 3 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 3 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 3 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 3 hypotheses
Olfactory Mucosa, Blood and Urine for Identification of
clinical · Pages share 3 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 3 hypotheses
Swedish BioFINDER 2 Study: Biomarkers and Neurodegenera
clinical · Pages share 3 hypotheses
Beta-Propeller Protein-Associated Neurodegeneration (BP
disease · Pages share 3 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (8 edges)
Novel TKIs
treats
Brain metastases
Novel Drug Delivery Systems
treats
Chemotherapy Resistance
Novel Androgen Agents
modulates
Quality Of Life
Novel Pharmacologic Therapies
treats
Generalized Myasthenia Gravis
Novel Biomarkers
biomarker_for
Generalized Myasthenia Gravis
Novel Targeted Treatments
promotes
Minimal Manifestation Status
C-Terminal Truncating Kif5A Mutations
causes
Novel Kif5A-Associated Disorder
Hub Genes (9 Novel)
biomarker_for
COPD
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.